BridgeBio Pharma Income from Continuous Operations 2018-2024 | BBIO
BridgeBio Pharma income from continuous operations for the twelve months ending September 30, 2024 was $-0.446B, a 28.42% decline year-over-year.
- BridgeBio Pharma annual income from continuous operations for 2023 was $-0.653B, a 34.79% increase from 2022.
- BridgeBio Pharma annual income from continuous operations for 2022 was $-0.485B, a 17.36% decline from 2021.
- BridgeBio Pharma annual income from continuous operations for 2021 was $-0.586B, a 16.02% increase from 2020.